Navigation Links
Synthetic lethality: A new way to kill cancer cells
Date:2/22/2010

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy ones.

BRCA and PARP are two key players in DNA repair and have different but complementary functions in the cell. Loss of the BRCA protein still allows the cell to survive but greatly increases its chances of becoming cancerous through the accumulation of mutations. The loss of both proteins, however, kills the cell in a process called synthetic lethality.

Researchers, by using drugs to block the activity of PARP in cells missing BRCA, such as those found in certain breast and ovarian cancers, can help spare healthy, non-cancerous cells because they have functional BRCA and are not affected by the loss of PARP. Thus, only cancer cells without functional BRCA protein are killed by drugs that inhibit PARP.

Recent clinical trials have shown that cancers caused by mutations that knock out BRCA activity can be controlled by blocking PARP activity with specific drugs. Patients were treated with traditional anticancer drugs alone or in combination with one of two new PARP inhibitors, olaparib or BSI-201.

Bates notes that patients on combination therapy had improved "[disease] progression-free survival, and overall survival" as compared to patients treated with traditional drugs alone.

Bates is optimistic about the promise of combining PARP inhibitors with existing cancer drugs. She says that the results of these clinical trials "have provided proof of principle in achieving synthetic lethality" with PARP-inhibiting drug
'/>"/>

Contact: Steve Pogonowski
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Biotech, nanotech and synthetic biology roles in future food supply explored
2. Synthetic protein mimics structure, function of metalloprotein in nature
3. Synthetic biology offers new opportunities for interdisciplinary collaboration
4. New synthetic molecules trigger immune response to HIV and prostate cancer
5. Sun or shade: Pecan leaves photosynthetic light response evaluated
6. Synthetic cells shed biological insights while delivering battery power
7. Understanding a cells split personality aids synthetic circuits
8. Nanotechnology and synthetic biology: What does the American public think?
9. Synthetic Biology Project receives 2 National Science Foundation grants
10. July 9-10 symposium on synthetic biology
11. Synthetic catalyst mimics natures hydrogen economy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Synthetic lethality: A new way to kill cancer cells
(Date:2/13/2015)... 13, 2015 ACT Genomics Co., Ltd., ... to transform cancer genomic information into precision diagnosis ... has raised US$ 8 million in the its first ... Taipei, Taiwan , ACT Genomics has ... the aim to implement next generation sequencing (NGS) ...
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... been implicated in the pathogenesis of several ... and amyotrophic lateral sclerosis. Oxidative stress is ... species, which can induce mitochondrial DNA mutations, ... permeability, and influence Ca2+ homeostasis and mitochondrial ...
... Results from a clinical trial of eteplirsen, a drug ... therapy allows participants to walk farther than people treated ... vital to muscle growth and health. The study, led ... Children,s Hospital, is the first of its kind to ...
... CINCINNATI, OH: August 7, 2013 The International Rett ... not-for-profit organization that funds novel research for treatments and ... G. Kaminsky, Ph.D., received two incredibly prestigious awards at ... past June. Dr. Steven Kaminsky leads the ...
Cached Biology News:New drug improves walking performance for Duchenne muscular dystrophy patients 2New drug improves walking performance for Duchenne muscular dystrophy patients 3International Rett Syndrome Foundation chief science officer receives prestigious military awards 2
(Date:2/26/2015)... Calif. , Feb. 26, 2015  NuGene ... age-defying aesthetic products for skin and hair rejuvenation, ... Relations as agency of record for investor relations ... to improve our distribution, sales and diversification strategies ... to current and prospective shareholders," stated Ali Kharazmi ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which ... N. Morial Convention Center in New Orleans, Louisiana, ... 19, 2015) displaying products and services used by ... labs. The Exposition will offer the latest innovations ... analytical chemistry; drug discovery; nanotechnology; life sciences to ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2RURO Releases FreezerPro® version 6.2 2Regis Extends cGMP Services to Oncology Market 2
... Ltd, a specialty,biopharmaceutical company focused on controlling ... successfully raised GBP11 million ($21.8,million) in an ... new investors Goldman Sachs and Invesco Perpetual, ... and Lansdowne,Partners., "Completing this financing is ...
... at Northwestern Universitys Center for Quantum Devices (CQD) ... detecting single photons in the ultraviolet region (360-200 ... only available technology in the short wavelength UV ... detection sensitivity. However, these fragile vacuum tube devices ...
... Researchers at Rensselaer Polytechnic Institute and Polyset Company ... could lead to dramatic cost savings and efficiency ... , Along with allowing enhanced performance and cost ... called polyset epoxy siloxane (PES), should also enable ...
Cached Biology Technology:Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding 2Tiny avalanche photodiode detects single UV photons 2New polymer could improve semiconductor manufacturing, packaging 2
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
... EC3 Darkroom is designed for imaging of ... EC3 systems offer direct control for users ... settings by hand , A range of ... system for all fluorescent and chemiluminescent applications ...
... known as smooth muscle cell specific protein, is ... various tissues such as intestine, lung and uterus. ... calponin. SM22 alpha expression has been reported in ... vascular and visceral forms. It is also reported ...
... system is designed for multiple user laboratories ... for TLC applications. The MultiDoc-It is available ... enclosure provides a darkroom environment and protects ... Use image capture and enhancement , ...
Biology Products: